Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradationOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study asked whether gut microbiome signatures linked to colorectal cancer (CRC) hold up reliably across different patient cohorts and populations. The researchers meta-analyzed fecal metagenomic sequencing data to identify microbial taxa and functional pathways that consistently distinguish CRC from controls. They also examined the microbiome's functional potential, comparing metabolic pathways such as gluconeogenesis, putrefaction, fermentation, and choline degradation between CRC and control samples. Finally, they built and tested predictive microbiome signatures for CRC diagnosis.
Who was studied?
The analysis drew on 969 fecal metagenomes assembled from five publicly available datasets plus two newly collected cohorts, with findings further validated on two additional independent cohorts. The abstract does not specify demographic details such as age, sex, or geographic origin of participants. This design represents a large-scale, multi-population pooling of existing and new CRC and control stool metagenome datasets rather than a single defined patient group.
What were the most important findings?
The gut microbiome in CRC showed reproducibly higher richness than in controls (P < 0.01), partly driven by expansions of species normally derived from the oral cavity. Functional meta-analysis linked gluconeogenesis and putrefaction/fermentation pathways to CRC, while stachyose and starch degradation pathways were associated with controls. A predictive microbiome signature trained across multiple datasets achieved consistently high accuracy in datasets and independent validation cohorts it had not been trained on, with an average area under the curve of 0.84. Pooled raw metagenome analysis also found the choline trimethylamine-lyase gene overabundant in CRC samples (P = 0.001), linking microbiome choline metabolism to CRC.
What are the greatest implications of this study?
By validating microbial richness increases, specific functional pathway shifts, and a diagnostic signature across multiple independent cohorts, this study strengthens the case that gut microbiome-based biomarkers for CRC can generalize beyond a single population. The identification of an overabundant choline trimethylamine-lyase gene points to microbiome-driven choline degradation as a mechanistic link worth further investigation in CRC. The high, cross-cohort predictive accuracy (AUC 0.84) supports the feasibility of microbiome-based tools as non-invasive adjuncts for CRC screening or risk stratification.